Alimta

... Bloomberg.com: Top Worldwide Updated: New York: Jan 26 15:00London: Jan 26 20:00Tokyo: Jan 27 05:00 : Top Worldwide Top Worldwide Regions Markets Economy/Politics Commentary Sports Culture RESOURCES: Bloomberg TV Bloomberg Radio Markets Top Worldwide E-Mail This Story Printer-Friendly Format Pfizer, Drugmakers Losing Republican Support to Prevent Legal Drug Imports U.S.

Stocks Advance for Second Day as Texas Instruments, Lilly Shares Gain Altria's Net Income Declines 6.9 Percent; Sales Gain Amid Dollar's Drop Lilly Has $2.4 Mln Loss on Tax Costs; Sales Rise 5% (Correct) Listen Lilly Has $2.4 Mln Loss on Tax Costs; Sales Rise 5% (Correct) (Corrects seventh paragraph to add dropped word.) By Kerry Dooley Jan.

26 (Bloomberg) - Eli Lilly & Co.

had a fourth-quarter loss on taxes to return $8 billion in profits to the U.S.

from abroad.

Sales rose 5 percent, boosted by the attention-deficit drug Strattera and the cancer treatment Gemzar.

The net loss of $2.4 million, Lilly's first in seven years, was less than a cent a share and compared with net income of $747.2 million, or 69 cents, a year earlier.

The recent quarter included $465 million in tax costs on overseas profits being brought to the U.S.

under a one-year tax holiday, the Indianapolis-based company said in a statement today.

Newer medicines such as Strattera, Read more...